Relevant bibliographies by topics / Cystic fibrosis Patients Biography

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Cystic fibrosis Patients Biography'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cystic fibrosis Patients Biography.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cystic fibrosis Patients Biography"

1

Radlovic, Nedeljko. "Cystic fibrosis." Srpski arhiv za celokupno lekarstvo 140, no. 3-4 (2012): 244–49. http://dx.doi.org/10.2298/sarh1204244r.

Full text
Abstract:
Cystic fibrosis (CF) is a multisystemic autosomal recessive disease caused by a defect in the expression of CFTR protein, i.e. chloride channel present in the apical membrane of respiratory, digestive, reproductive and sweat glands epithelium. It primarily occurs in the Caucasians, while being considerably or exceptionally rare in persons of other races. Absence, deficit or structural and functional abnormalities of CFTR protein lead to mucosal hyperconcentration in the respiratory, digestive and reproductive systems and malabsorption of chloride and sodium in the sweat glands. Thus, the clinical features of patients? with CF are predominated by respiratory, digestive and reproductive disorders, as well as the tendency to dehydration in the condition of increased sweating. Beside genotype variations, the degree of disease manifestation is also essentially influenced by various exogenous factors, such as the frequency and severity of respiratory infections, the level of aero-pollution, quality of immunoprophylaxis, patients? nutritional condition and other. Chloride concentration of over 60 mmol/L in sweat, a high level of immunoreactive chymotrypsinogen in blood and the verification of homozygous mutation of CFTR gene are the basic methods in the diagnostics of the disease. CF belongs to the group of severe and complex chronic diseases, and therefore requires multidisciplinary therapeutic approach. Owing to the improvement of healthcare provision, most patients with CF now survive into adulthood. In addition, their quality of life is also considerably improved.
APA, Harvard, Vancouver, ISO, and other styles
2

Hadj Fredj, Sondess, Slaheddine Fattoum, Abdelraouf Chabchoub, and Taieb Messaoud. "First report of cystic fibrosis mutations in Libyan cystic fibrosis patients." Annals of Human Biology 38, no. 5 (February 18, 2011): 561–63. http://dx.doi.org/10.3109/03014460.2011.557090.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Onay, Tuncer, Julian Zielenski, Ozlem Topaloglu, Nalan Gokgoz, Hulya Kayserili, Memnune Yuksel Apak, Yildiz Camcioglu, et al. "Cystic Fibrosis Mutation and Associated Haplotypes in Turkish Cystic Fibrosis Patients." Human Biology 73, no. 2 (2001): 191–203. http://dx.doi.org/10.1353/hub.2001.0022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Standen, Jen. "Cystic fibrosis." InnovAiT: Education and inspiration for general practice 13, no. 1 (November 27, 2019): 39–46. http://dx.doi.org/10.1177/1755738019883322.

Full text
Abstract:
In the UK over 10 000 people live with cystic fibrosis (CF), with 1-in-25 people being carriers of the disease. Multidisciplinary care is provided by tertiary care CF centres, with or without local secondary service shared care agreements. There are still, however, several reasons why CF sufferers or their families present to their GPs. This article aims to provide a brief overview of CF and its management. It also gives the information needed to guide patients about genetic testing and neonatal screening for the disease.
APA, Harvard, Vancouver, ISO, and other styles
5

Westwood, A. T. R. "Splenectomy in cystic fibrosis patients." Archives of Disease in Childhood 89, no. 11 (November 1, 2004): 1078. http://dx.doi.org/10.1136/adc.2004.051508.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pozler, O., H. Vanicek, D. Neumann, and J. Bures. "ELECTROGASTROGRAPHY IN CYSTIC FIBROSIS PATIENTS." Journal of Pediatric Gastroenterology and Nutrition 32 (April 2001): S54. http://dx.doi.org/10.1097/00005176-200104001-00043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Grody, Wayne W. "Cystic Fibrosis." Archives of Pathology & Laboratory Medicine 123, no. 11 (November 1, 1999): 1041–46. http://dx.doi.org/10.5858/1999-123-1041-cf.

Full text
Abstract:
Abstract Objective.—To review the current status of scientific knowledge and opinion regarding molecular genetic testing of mutations in the CFTR gene for purposes of diagnosis and population carrier screening of cystic fibrosis (CF). Data Sources.—Published research findings on the nature of the CFTR gene, pilot population screening studies in the United States and Europe, and ongoing deliberations of professional and governmental agencies considering implementation of widespread testing. Study Selection.—Findings relevant to the molecular heterogeneity of CFTR mutations and its implications for population carrier screening were considered. Data Extraction.—Information was extracted from studies published by us and others, as made available to recent consensus panels and professional committees. Data Synthesis.—These data were reevaluated in light of recent movements in professional and public policy regarding acceptability and desirability of widespread CF mutation testing. Effects to date of such testing on patient outcomes is reported. Conclusions.—The ability to test for CFTR mutations at the molecular level has already improved the diagnosis of symptomatic patients and expanded the reproductive options of family members of CF patients. The same technology also holds promise of identifying asymptomatic carriers and at-risk couples without family history in the general population so that they too might be offered prenatal diagnosis or other options. However, a number of key questions remain to be worked out before a widespread national screening program can be put into practice. These include the target population to be offered testing (the entire population vs high-risk ethnic groups), the size and nature of the mutation test panel (universal vs ethnic specific), the inclusion or exclusion of CFTR variants that do not cause classical CF, the optimal testing technology, appropriate standards for laboratory quality assurance, and the development of sufficient educational materials and genetic counseling resources for test delivery, reporting, and interpretation. The answers to these questions will be relevant not only to CF testing but also to many other large-scale molecular genetic screening programs being considered in the future.
APA, Harvard, Vancouver, ISO, and other styles
8

Balanetchi, L., R. Selevestru, A. Cotoman, D. Rotaru-Cojocari, and S. Sciuca. "P099 Evaluation by plethismography of cystic fibrosis and non-cystic fibrosis patients." Journal of Cystic Fibrosis 20 (2021): S69. http://dx.doi.org/10.1016/s1569-1993(21)01125-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bar-Yoseph, Ronen, Anat Ilivitzki, Dan M. Cooper, Michal Gur, Gur Mainzer, Fahed Hakim, Galit Livnat, et al. "Exercise capacity in patients with cystic fibrosis vs. non-cystic fibrosis bronchiectasis." PLOS ONE 14, no. 6 (June 13, 2019): e0217491. http://dx.doi.org/10.1371/journal.pone.0217491.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bingol, A., M. G. Ertosun, R. Artan, A. Yilmaz, E. Mihci, B. N. Guzel, M. Erman Akar, et al. "35 Cystic fibrosis transmembrane regulator mutations in Turkish patients with cystic fibrosis." Journal of Cystic Fibrosis 13 (June 2014): S55. http://dx.doi.org/10.1016/s1569-1993(14)60172-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cystic fibrosis Patients Biography"

1

Durham, Dixie Lea. "Survey of adult cystic fibrosis patients and parents of cystic fibrosis patients on nutrition education." [Boise, Idaho] : Boise State University, 2009. http://scholarworks.boisestate.edu/td/8/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Fortin, Carol M. "Creatinine Clearance Estimation in Cystic Fibrosis Patients." The University of Arizona, 2006. http://hdl.handle.net/10150/624684.

Full text
Abstract:
Class of 2006 Abstract
Objectives: To develop a new equation to predict creatinine clearance specific for cystic fibrosis patients. Methods: A literature review was performed to capture data on the daily creatinine excretion in CF patients in relation to age, weight, height, and other physiologic variables. Nonlinear mixed effect modeling was then used to develop an equation to estimate creatinine clearance using individual covariates. The performance of the new equation developed was compared to the Cockcroft and Gault method in a CF population (age > 16 years). Results: A database of individual patient data from a previously published study of 19 patients was created. Significant covariates for model development included actual body weight, sex, and serum creatinine. The final candidate model was: 5.62× ABW0.67 CrCl = sCr(mg / dl) × 0.649( female) Conclusions: The results of the mean absolute error and root mean squared error calculations show that the new equation resulted in less bias and better precision than Cockcroft-Gault, Jeliffe I, and Jeliffe II based on the limited data available. However, these conclusions are limited in that the only evaluation data available was the same data that was used for model development.
APA, Harvard, Vancouver, ISO, and other styles
3

Rucker, Bianca M. G. "A sexual profile of adults with cystic fibrosis : the sexuality and sexual concerns of adults with cystic fibrosis." Thesis, University of British Columbia, 1987. http://hdl.handle.net/2429/26909.

Full text
Abstract:
Only in recent years have diagnostic and therapeutic advances lengthened the life expectancy for patients who have cystic fibrosis sufficiently to allow some of them to live into adulthood. Health care professionals have been focusing on survival issues and are only recently beginning to look at quality of life issues, such as sexuality, of these patients. The purpose of the study was to create a sexual profile of adults with cystic fibrosis which would describe their sexuality and sexual concerns. A questionnaire was developed and sent to all of the adult cystic fibrosis patients (19 years of age and older) in British Columbia (50 patients), all of whom attend the Shaughnessy Hospital Adult CF Clinic in Vancouver. The 62% response rate provided data for the sexual profile which indicated that 90% of the respondents were sexually active. Only a small number of subjects reported sexual difficulties in their relationships. Concerns about the impact of CF on their sexuality included: the effect of the potentially limited lifespan on their relationships, practical considerations such as fatigue and coughing during sexual activity, and poor body image. A major issue for CF males is that most of them are infertile due to CF. How and when men should be told about this issue was an important question for the CF Clinic staff. Responses indicated that men thought they should find out from either the physician in the pediatric CF clinic or the physician in the adult CF clinic. Furthermore, 100% of the men suggested that this issue be discussed with males before the age of 19 years. Limitations and recommendations of the research are discussed. A major recommendation is for physicians and other health care professionals in CF clinics to give patients the opportunity to discuss sexual issues.
Education, Faculty of
Educational and Counselling Psychology, and Special Education (ECPS), Department of
Graduate
APA, Harvard, Vancouver, ISO, and other styles
4

Bhakta, Dharti, Kalyn Schmidt, Aubrey Silvester, Marcella Honkonen, and Hanna Phan. "Impact on Vitamin D Status in Cystic Fibrosis Patients After Implementation of 2012 Cystic Fibrosis Foundation Guidelines." The University of Arizona, 2015. http://hdl.handle.net/10150/614103.

Full text
Abstract:
Class of 2015 Abstract
Objectives: The primary objective of the study was to evaluate for change in vitamin D levels and regimens in cystic fibrosis (CF) patients following implementation of the 2012 Cystic Fibrosis Foundation (CFF) vitamin D guidelines. Secondary endpoints included clinician adherence to guideline recommendations for treatment and management of vitamin D deficiency. Methods: This retrospective chart review included CF patients with 25-hydroxy vitamin D (25(OH)D) levels from University of Arizona Medical Center (UAMC) between April 1, 2011-March 31, 2012 and July 1, 2012-June 30, 2013. Total 25(OH)D levels and vitamin D regimens were collected along with data on respiratory cultures, pulmonary function, and hospitalizations. Data were analyzed by Student’s T-tests and chi square analyses. Results: A total of 62 patients were included in the study. Mean 25(OH)D levels did not significantly differ between the study periods (28.9±10.5 ng/mL pre-guideline and 27.0±9.1 ng/mL post-guideline, p=0.158). Cholecalciferol use increased post-guideline (57.1%) versus pre-guideline (75.8%, p=0.027). Post-guideline cholecalciferol doses increased to 2836.5±2669.4 international units [IU] daily compared to 1518.0±912.0 IU daily pre-guideline (p<0.001). Clinician adherence to dose titration recommendations resulted in significant 25(OH)D level elevations (28.3±8.9 ng/mL versus 24.7±9.0, p=0.047). Conclusions: The prescribing pattern of clinicians significantly changed to reflect vitamin D regimens suggested by CFF guidelines. This finding suggests that had sufficient time been allowed following guideline implementation, a significant difference in 25(OH)D levels would have resulted. Additional research is needed concerning the effect of the guidelines on vitamin D status, clinical outcomes, and comorbidities.
APA, Harvard, Vancouver, ISO, and other styles
5

Rogers, Geraint Berian. "Molecular analysis of respiratory infections in cystic fibrosis patients." Thesis, King's College London (University of London), 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.407194.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Butler, Sarah Louise. "Pulmonary colonisation of patients with cystic fibrosis by Burkholderia cepacia." Thesis, University of Edinburgh, 1994. http://hdl.handle.net/1842/27646.

Full text
Abstract:
This thesis describes studies investigating the biological properties of B. cepacia, in particular those which may contribute to the organism's role as an opportunist pathogen and considers the host-bacterium interaction in CF including factors involved in early colonisation and the host immune response to B. cepacia colonisation. Emphasis is placed on studies of a highly transmissible or epidemic strain isolated in Edinburgh in 1989 and responsible for colonisation of CF patients in other regional CF centres. B. cepacia adhesion to respiratory mucin was measured in an ELISA-based mucin adherence assay. The majority of B. cepacia strains did not adhere to purified respiratory mucin. Interestingly, the epidemic strain exhibited the greatest degree of mucin adherence. Adhesion of B. cepacia to buccal epithelial cells studied by fluorescent labelling and flow cytometry also showed that the epidemic strain demonstrated greatest adhesion. The humoral immune response in CF patients colonised with B. cepacia was investigated by ELISA, incorporating B. cepacia LPS and by immunoblotting against LPS, flagella and outer membrane protein antigens. Elevated levels of specific anti-B. cepacia IgG, IgA and IgM were observed in patients chronically colonised by B. cepacia, especially in those patients colonised by the epidemic strain. Detection of anti-B. cepacia antibodies may aid in early diagnosis of B. cepacia colonisation, but as yet does not appear to have prognostic value. Evidence presented in this thesis indicates that B. cepacia persists in the CF respiratory tract despite a specific humoral immune response and causes bacteraemia despite being serum sensitive. These factors together with the intractability of B. cepacia to antimicrobial therapy and the close taxonomic relationship with the highly virulent Burkholderia pseudomallei, allows speculation that the association B. cepacia with CF may involve a stage of intracellular growth for survival.
APA, Harvard, Vancouver, ISO, and other styles
7

Meloff, Liann Rachel. "Assessment of eating disorder symptomatology in patients with cystic fibrosis." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2001. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp05/NQ64876.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Al-Baba, Sami. "Diagnosis and typing of psendomonas aeruginosa from cystic fibrosis patients." Thesis, Manchester Metropolitan University, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.533358.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kinirons, Martin J. "Oral and dental changes in patients suffering from cystic fibrosis." Thesis, Queen's University Belfast, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.317090.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nelson, J. W. "Pulmonary colonisation of patients with cystic fibrosis by Pseudomonas aeruginosa." Thesis, University of Edinburgh, 1991. http://hdl.handle.net/1842/19187.

Full text
Abstract:
Chronic respiratory colonisation by the adaptable opportunistic pathogen Pseudomonas aeruginosa is a major debilitating feature of the inherited disease cystic fibrosis (CF). This thesis considers various aspects of the pathogenesis of P.aeruginosa in CF, including the serological response to bacterial colonisation, and possible factors involved in early colonisation. Anti-P.aeruginosa lipopolysaccharide (LPS) antibodies in sera, saliva and sputa from patients with CF were measured by enzyme-linked immunosorbent assay (ELISA) incorporating either a polyvalent pseudomonas smooth LPS extract vaccine, or P.aeruginosa core, rough LPS. Elevated levels of anti-LPS IgG antibodies in serum, and IgA antibodies in saliva and sputum were demonstrated in patients chronically colonised by P.aeruginosa. Low levels of serum anti-LPS IgG antibodies were detected in some patients intermittently colonised by P.aeruginosa, but not in non-P.aeruginosa colonised patients. Anti-LPS IgA antibodies were detected in some of both intermittently and non-colonised patients. Immunoblot analysis of serum IgG and sputum IgA antibodies to P.aeruginosa LPS revealed a response directed towards O-antigenic LPS in the initial stages of pulmonary colonisation with non-mucoid P.aeruginosa and a response towards common core LPS during subsequent chronic infection with mucoid P.aeruginosa. Flagellar preparations from P.aeruginosa strains were characterised and used in ELISA and immunoblot studies to detect anti-P.aeruginosa flagellar antibodies in sera, saliva and sputum. Serum anti-flagellar IgG antibodies were detected, particularly in those CF patients intermittently or chronically colonised by P.aeruginosa. Antibodies to both type -a and -b flagella were detected; in some patients a pronounced antibody response to only one of the flagellar types was evident. Anti-P.aeruginosa LPS monoclonal antibodies (MAbs) were produced for use in a sandwich ELISA for the detection of P.aeruginosa in respiratory secretions of patients with CF. LPS defective mutants expressing only common core LPS were used to immunise mice for preparation of MAbs. Antibodies were screened in ELISA and the antigenic component(s) of LPS recognised by the most cross-reactive MAbs was checked by immunoblotting. Five IgG MAbs were characterised and found to recognise the core component of P.aeruginosa LPS. Two of the MAbs were particularly reactive against core LPS from all O-antigenic serotypes of P.aeruginosa and were included in the sandwich ELISA for detection of P.aeruginosa LPS. A biotin-streptavidin amplification system was used to increase assay sensitivity. The sensitivity of the assay was 0.1 ng/ml P.aeruginosa LPS; the assay was able to detect P.aeruginosa LPS in the respiratory secretions from patients with CF.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cystic fibrosis Patients Biography"

1

Stobbs, Alexander. A passion for living: The amazing story of a boy who makes every day matter. London: Hodder & Stoughton, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

A passion for living. Leicester: Ulverscroft, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

How Have I Cheated Death?: A Short and Merry Life with Cystic Fibrosis. London: Austin Macauley Publishers Ltd, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

author, Couture Jean 1952, ed. Pas d'obstacles assez grands!: Raccourcis et détours d'une survivante. (Montréal, Québec): Les Éditions de l'Homme, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dodson, Olin. Melissa's gift. Point Richmond, Calif: Ardenwood Books, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Run, Amy, run! [La Vergine, TN]: Trafford, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rothenberg, Laura. Breathing for a living: A memoir. New York: Hyperion, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Salty Baby: A memoir. Dublin: Hachette Books Ireland, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

I'll get to heaven before you do! Nashville: Abingdon Press, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Rothenberg, Laura. Breathing for a living: A memoir. New York: Hyperion, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cystic fibrosis Patients Biography"

1

Knutsen, Alan P., and Raymond G. Slavin. "Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis." In Cystic Fibrosis, 103–18. Totowa, NJ: Humana Press, 1990. http://dx.doi.org/10.1007/978-1-4612-0475-6_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Prober, Charles G. "The Impact of Respiratory Viral Infections in Patients with Cystic Fibrosis." In Cystic Fibrosis, 87–102. Totowa, NJ: Humana Press, 1990. http://dx.doi.org/10.1007/978-1-4612-0475-6_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Filbrun, Amy G., Thomas Lahiri, and Clement L. Ren. "Monitoring and Evaluation of Patients with Cystic Fibrosis." In Handbook of Cystic Fibrosis, 65–76. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-32504-0_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Iglewski, B. H. "Antibody Responses in Patients with Cystic Fibrosis." In The Pathogenesis of Bacterial Infections, 425–26. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-70351-5_46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Stuhrmann, Manfred, Thilo Dörk, Michael Krawczak, Margarete Dueck, Ulrich Banholzer, Jutta Domagk, Nicola Hoffknecht, et al. "Genotype-Phenotype Correlations in Cystic Fibrosis Patients." In Advances in Experimental Medicine and Biology, 97–103. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-5934-0_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Griffith, David E. "Nontuberculous Mycobacterial Lung Disease in Patients with Cystic Fibrosis." In Cystic Fibrosis in the 21st Century, 160–65. Basel: KARGER, 2005. http://dx.doi.org/10.1159/000088572.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ronchetto, Patrizia, Laura Fenu, Aldamaria Puliti, Marcella Devoto, Luca Romano, Giovanni Romeo, Laura Cremonesi, et al. "Frequency of Cystic Fibrosis Mutations Among Italian Patients." In Advances in Experimental Medicine and Biology, 387–90. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-5934-0_46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Alvarez de Garcia Tuñon, Sonia, and Heberto Reyes. "Pulmonary Infections in Venezuelan Patients with Cystic Fibrosis." In Cystic Fibrosis Pulmonary Infections: Lessons from Around the World, 139–48. Basel: Birkhäuser Basel, 1996. http://dx.doi.org/10.1007/978-3-0348-7359-8_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Malatack, James Joseph, and Tara Lynn Barto. "Depression and Anxiety in the Cystic Fibrosis Population." In Depression and Anxiety in Patients with Chronic Respiratory Diseases, 85–95. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7009-4_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Vagg, Tamara, Cathy Shortt, Claire Hickey, Joseph A. Eustace, Barry J. Plant, and Sabin Tabirca. "A mHealth Patient Passport for Adult Cystic Fibrosis Patients." In Lecture Notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering, 155–62. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-98551-0_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cystic fibrosis Patients Biography"

1

Bar-Yoseph, Ronen, Anat Ilivitzki, Michal Gur, Gur Mainzer, Fahed Hakim, Galit Livnat, Zeev Schnapp, et al. "Exercise capacity in patients with cystic fibrosis vs non-cystic fibrosis bronchiectasis." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.oa484.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zhao, Zhanqi, Knut Moller, Rainald Fischer, and Ullrich Muller-Lisse. "Regional Obstruction in Cystic Fibrosis Patients." In 2011 5th International Conference on Bioinformatics and Biomedical Engineering (iCBBE). IEEE, 2011. http://dx.doi.org/10.1109/icbbe.2011.5780367.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dalcin, Paulo de Tarso R., Bruna Ziegler, Andréia K. Fernandes, Paulo Roberto S. Sanches, Danton P. da Silva-Junior, and Paulo Ricardo O. Thome. "Dyspnea Perception In Cystic Fibrosis Patients." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a2809.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Murugesan, V., S. N. Mahmood, and E. Oweis. "Cystic Fibrosis: A National Study of Adult Patients Admitted for Cystic Fibrosis in 2014." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4636.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Çobanoğlu, Fatma Nazan, Deniz Doğru Ersöz, Erkan Çakır, Tuğba Şişmanlar Eyüboğlu, Sevgi Pekcan, Güzin Cinel, Ebru Yalçın, et al. "Cystic Fibrosis Patients Eligible for Modulator Drugs: Data from Cystic Fibrosis Registry of Turkey." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa4518.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ergenekon, Pinar, Emine Atag, Nilay Bas İkizoglu, Cansu Yilmaz Yegit, Yasemin Gokdemir, Ela Erdem Eralp, and Bulent Karadag. "Characteristics of cystic fibrosis patients diagnosed after false negative cystic fibrosis newborn screening results." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa4523.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Graff, G. R., B. J. Sankoorikal, and A. Mathew. "Re-Evaluating EPI in Cystic Fibrosis Patients." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a5324.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Fukushima, Lynn K., Lorelie Evangelista, Kamyar Afshar, and Adupa P. Rao. "Cognitive Dysfunction In Adult Cystic Fibrosis Patients." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a1088.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Vezir, D., B. Balcan, D. Kocakaya, C. Çınar, Ş. Olgun Yıldızeli, and B. Ceyhan. "Clinical impact of Obstructive Sleep Apnea on Depression in patients with Cystic Fibrosis and non-Cystic Fibrosis Bronchiectasis patients." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.1791.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Weintraub, Z., and M. J. Stephen. "Attitudes of Cystic Fibrosis Patients Towards Lung Transplant." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4333.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cystic fibrosis Patients Biography"

1

Borisova, Dayana, Tanya Strateva, Tsvetelina Paunova-Krasteva, Ivan Mitov, and Stoyanka Stoitsova. Phenotypic Investigation of Paired Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients Prior- and Post-tobramycin Treatment. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, August 2018. http://dx.doi.org/10.7546/crabs.2018.08.05.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Barros-Poblete, Marisol, Rodrigo Torres-Castro, Mauricio Henríquez, Anita Guequen, Isabel Blanco, and Carlos Flores. Dysbiosis as a prognostic factor for clinical worsening in chronic respiratory disease: A systematic review and metanalysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0089.

Full text
Abstract:
Review question / Objective: Is dysbiosis a prognostic factor for clinical worsening in patients with chronic respiratory diseases?. Condition being studied: Dysbiosis, defined as changes in the quantitative and qualitative composition of the microbiota. Eligibility criteria: Over 18 years old adult patients with chronic respiratory diseases clinical diagnosis (cystic fibrosis, chronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis, interstitial lung disease, sarcoidosis, bronchiectasis, non-CF bronchiectasis, pulmonary hypertension) according to the International Statistical Classification of Diseases and Related Health Problems (ICD) from OMS) and international guidelines of each disease.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cystic fibrosis Patients Biography' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography